Ionis Partners With Metagenomi To Expand Its Genetic Medicines Capabilities
Ionis will pay $80m up front to Metagenomi to access its next-generation gene-editing technology to jointly research new therapies for up to four genetic targets.
Ionis will pay $80m up front to Metagenomi to access its next-generation gene-editing technology to jointly research new therapies for up to four genetic targets.